Dataset Information

Circulating resistin levels and risk of multiple myeloma in three prospective cohorts.

ABSTRACT: BACKGROUND:Resistin is a polypeptide hormone secreted by adipose tissue. A prior hospital-based case-control study reported serum resistin levels to be inversely associated with risk of multiple myeloma (MM). To date, this association has not been investigated prospectively. METHODS:We measured resistin concentrations for pre-diagnosis peripheral blood samples from 178 MM cases and 358 individually matched controls from three cohorts participating in the MM cohort consortium. RESULTS:In overall analyses, higher resistin levels were weakly associated with reduced MM risk. For men, we observed a statistically significant inverse association between resistin levels and MM (odds ratio, 0.44; 95% confidence interval (CI) 0.24-0.83 and 0.54; 95% CI 0.29-0.99, for the third and fourth quartiles, respectively, vs the lowest quartile; Ptrend=0.03). No association was observed for women. CONCLUSIONS:This study provides the first prospective evidence that low circulating resistin levels may be associated with an increased risk of MM, particularly for men.

SUBMITTER: Santo L

PROVIDER: S-EPMC5674102 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Circulating resistin levels and risk of multiple myeloma in three prospective cohorts.

Santo Loredana L Teras Lauren R LR Giles Graham G GG Weinstein Stephanie J SJ Albanes Demetrius D Wang Ye Y Pfeiffer Ruth M RM Lan Qing Q Rothman Nathaniel N Birmann Brenda M BM Colditz Graham A GA Pollak Michael N MN Purdue Mark P MP Hofmann Jonathan N JN

British journal of cancer 20170822 8

<h4>Background</h4>Resistin is a polypeptide hormone secreted by adipose tissue. A prior hospital-based case-control study reported serum resistin levels to be inversely associated with risk of multiple myeloma (MM). To date, this association has not been investigated prospectively.<h4>Methods</h4>We measured resistin concentrations for pre-diagnosis peripheral blood samples from 178 MM cases and 358 individually matched controls from three cohorts participating in the MM cohort consortium.<h4>R ...[more]

PMID: 28829767

Similar Datasets

Project description:BackgroundExperimental and clinical studies have implicated certain chemokines and angiogenic cytokines in multiple myeloma (MM) pathogenesis. To investigate whether systemic concentrations of these markers are associated with future MM risk and progression from its precursor, monoclonal gammopathy of undetermined significance (MGUS), we conducted a prospective study within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.MethodsWe measured concentrations of 45 immunologic and pro-angiogenic markers in sera from 241 MM case patients, 441 participants with nonprogressing MGUS, and 258 MGUS-free control participants using Luminex-based multiplex assays and enzyme-linked immunosorbent assays. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression. We also evaluated absolute risk of progression using weighted Kaplan-Meier estimates. All statistical tests were two-sided.ResultsPrediagnostic levels of six markers were statistically significantly elevated among MM case patients compared with MGUS-free control participants using a false discovery rate of 10% (EGF, HGF, Ang-2, CXCL12, CCL8, and BMP-9). Of these, three angiogenesis markers were associated with future progression from MGUS to MM: EGF (fourth vs first quartile: OR?=?3.01, 95% CI = 1.61 to 5.63, P trend = .00028), HGF (OR = 2.59, 95% CI = 1.33 to 5.03, P trend = .015), and Ang-2 (OR = 2.14, 95% CI = 1.15 to 3.98, P trend = .07). A composite angiogenesis biomarker score substantially stratified risk of MGUS progression to MM beyond established risk factors for progression, particularly during the first 5?years of follow-up (areas under the curve of 0.71 and 0.64 with and without the angiogenesis marker score, respectively).ConclusionsOur prospective findings provide new insights into mechanisms involved in MM development and suggest that systemic angiogenesis markers could potentially improve risk stratification models for MGUS patients.

Dataset Information

Circulating resistin levels and risk of multiple myeloma in three prospective cohorts.

Publications

Circulating resistin levels and risk of multiple myeloma in three prospective cohorts.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets